In the setting of acute coronary syndromes, dual antiplatelet therapy, which combines aspirin with a P2Y12 inhibitor, such as clopidogrel, prasugrel, or ticagrelor, has demonstrated superior efficacy over aspirin alone, with prasugrel and ticagrelor offering more rapid and potent effects. This evidence concerns the gene P2RY12 and acute coronary syndrome.